Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology

被引：3

作者：

Shi, Jian-Xin ^{[1
,2
]}

Cai, Xiao-Qun ^{[1
]}

Zhao, Ze-Hao ^{[1
]}

Deng, Yu ^{[1
]}

Zhou, Zhi-Kun ^{[1
]}

机构：

[1] Guangdong Med Univ, Dept Pharm, 1 Xincheng Dadao,Songshan Lake Sci & Technol Ind P, Dongguan 523808, Peoples R China

[2] Guangdong Med Univ, Huizhou Womens & Childrens Hosp, 10 Daling Rd, Huizhou 516001, Peoples R China

来源：

EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2022年 / 2022卷

基金：

中国国家自然科学基金;

关键词：

BONE; BISPHOSPHONATES;

D O I：

10.1155/2022/8769531

中图分类号：

R [医药、卫生];

学科分类号：

100218 [急诊医学];

摘要：

Osteoclasts (OCs) have been the unique cell type exhibiting the bone-resorption activity in body. It is important to identify drugs to resist osteoclastogenesis to manage the bone-loss disorders. Huangqi Sanxian decoction (HQSXD) is utilized for the treatment of postmenopausal osteoporosis (PMOP) for a long history in East Asia. This work aimed to examine HQSXD's activity in OC differentiation. Based on staining with tartrate-resistant acid phosphatase (TRAP), it was found that HQSXD suppressed OC generation under the induction of RANKL produced in the bone marrow-derived monocytes/macrophages (BMMs), with no cytotoxic effect. Later analysis like molecular exploration and network pharmacology (NP) suggested the role of HQSXD in suppressing genes associated with osteoclastogenesis via PI3K/Akt-mediated mechanism dose-dependently. This work might illustrate the molecular pharmacological mechanism involved in HQSXD's effect on treating OC-associated disorders. Moreover, NP was found to modernize traditional Chinese medicine (TCM) research.

引用

页数：11

共 33 条

[1]

Long-term use of bisphosphonates in osteoporosis [J].